As­traZeneca spot­lights first-in-hu­man da­ta for B7-H4-tar­get­ing ADC in en­dome­tri­al can­cer

As­traZeneca is fine-tun­ing plans for a Phase 3 study for its B7-H4-tar­get­ing ADC af­ter the drug pro­duced en­cour­ag­ing re­sponse and sur­vival re­sults in en­dome­tri­al can­cer …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER